A $60 million credit facility was granted to Metabolon, a firm headquartered in Morrisville, North Carolina, that specializes in offering metabolomics solutions for applications in life science research, diagnostics, pharmaceutical development, and precision medicine.
Investor
- Trinity Capital
Use of funds
The firm plans to utilize the money to further research and development activities to improve its metabolomics platform and to further boost its expansion strategies. Its objectives for international expansion, including measures for market penetration and strategic alliances, will also be supported by the funding.
“As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. With this financing, we will be able to further establish our leadership in the metabolomics field, spur innovation, and develop faster than ever before.”
Rohan (Ro) Hastie
About Metabolon
With a purpose to provide biochemical data and insights that enhance and expedite the effect of life sciences research and complement other “omics” technologies, Metabolon, the world leader in metabolomics, is led by CEO Rohan (Ro) Hastie. With over 20 years of experience, over 10,000 projects completed, over 3,000 articles published, and certifications in ISO 9001:2015, CLIA, and CAP, Metabolon has created scientific, technological, and bioinformatics methods. It has a sizable proprietary metabolomics reference collection that powers its Global Discovery Panel. Its knowledge of data and translational science speeds up research and improves development success by assisting clients and collaborators in addressing some of the most difficult and urgent problems in the life sciences. From product life-cycle management and clinical trials to discovery, the firm supports customer needs with scalable, configurable multiomics solutions, such as lipidomics and metabolomics.
